American Heart Association Scientific Sessions 2015
361 - Infused CD34 Cell Dose, Not Bone Marrow CD34+ Cell Content, Improves Clinical Outcomes and LVEF in Patients with Left Ventricular Dysfunction Post STEMI: Results of the PreSERVE-AMI Trial November 9, 2015, 4:15 - 4:30 PM Authors Arshed Quyyumi, Emory Univ, Atlanta, GA; Dean J Kereiakes, The Christ Hosp Heart and Vascular Ctr and The Lindner Ctr for Res and Education, Cincinatti, OH; David M Shavelle, Univ of Southern California, Los Angeles, CA; Timothy D Henry, Cedars-Sinai Heart Inst, Los Angeles, CA; Ahmed Abdel-Latif, Univ of Kentucky, Lexington, KY; Catalin Toma, Univ of Pittsburgh Medical Ctr, Pittsburgh, PA; Gregory Barsness, Mayo Clinic, Rochester, MN; Steve C Frohwein, Emory St Josephs Hosp, Atlanta, GA; Richartd A Schatz, Scripps Health, La Jolla, CA; Martin Cohen, Westchester Medical Ctr, Valhalla, NY; Charles Davidson, NorthWestern, Chicago, IL; Nabil Dib, Dignity Health Medical Group, Gilbert, AZ; Marc Klapholz, Rutgers New Jersey Medical Sch, Newark, NJ; Gary L Schaer, Rush Univ Medical Ctr, Chicago, IL; Alejandro Vasquez, Huntsville Hosp, Hutsville, AL; Thomas J Moss, AnnaMaria Kanakaraj, Vitaly Druker, Ken Harper, Caladrius Biosciences, New York, NY; Amy Chung, Caladrius Biosciences, Inc, Irvine, CA; Candice Junge, Caladrius Biosciences, Irvine, CA; Robert Preti, Caldrius Biosciences, Allendale, NJ; Robin Smith, Caladrius Biosciences, New York, NY; David J Mazzo, Caldrius Biosciences, New York, NY; Andrew Pecora, Hackensack MC, Hackensack, NJ; Douglas W Losordo, Caladrius Biosciences, New York, NY
